Invesco Variable Rate Preferred ETF News - VRP | Aktien Amerikanische Börse

Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update

LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU...

Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANC...

LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a...

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic...

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in...

Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

Reported positive Phase 2b results in symptomatic patients with moderate to severe COPD with nebulized...

Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update

LONDON, April 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a...

Verona Pharma plc: Results of AGM

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a...

Update on AGM Procedure

LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or...

Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now...

2019 Annual Report and Accounts and Notice of AGM

LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a...

Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

Post-period end, reported positive top-line Phase 2b results with nebulized ensifentrine and senior management...

Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a...

Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

LONDON, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a...

Verona Pharma Announces Senior Management Changes

Dr. David Zaccardelli appointed President and Chief Executive Officer Mark W. Hahn appointed Chief Financial...

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium T...

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Invesco Variable Rate Preferred ETF (VRP)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

VRP Nachrichten

Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANC...

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic...

Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update

Verona Pharma plc: Results of AGM

Update on AGM Procedure

Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

2019 Annual Report and Accounts and Notice of AGM

Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

Verona Pharma Announces Senior Management Changes

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium T...

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Invesco Variable Rate Preferred ETF (VRP) News

Invesco Variable Rate Preferred ETF (VRP)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

VRP Nachrichten

Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANC...

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic...

Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update

Verona Pharma plc: Results of AGM

Update on AGM Procedure

Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

2019 Annual Report and Accounts and Notice of AGM

Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

Verona Pharma Announces Senior Management Changes

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium T...

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen